PIK3CA and neoplasm: However, a pooled analysis of two trials evaluating the combined biomarkers of KRAS, NRAS, BRAF, and PIK3CA showed a significantly reduced benefit from anti-EGFR therapy in patients with any mutant tumor compared with patients with all wt tumors (interaction tests P < 0.05 for PFS, OS, and ORR).